Abstract |
A placebo-controlled study of Ramipril on total and intrarenal flow distribution was carried out in 7 patients with essential hypertension. Cortical nephron flow was measured using radiolabelled tubular secreted radiopharmaceuticals 123I orthoidohippurate or 99mTc mercaptoacetyl triglycine by the transit time distribution technique. Both systolic and diastolic blood pressure were reduced significantly by Ramipril without significant changes in an index of cardiac output or in effective renal plasma flow. Cortical nephron flow increased from 207 +/- 7 to 257 +/- 21 ml/min (mean +/- SEM) p less than 0.05 and the percentage of flow to cortical nephrons increased by 6% (p = 0.05). Ramipril corrects the reduced cortical nephron flow found in essential hypertension.
|
Authors | A M al-Nahhas, C C Nimmon, K E Britton, M J Carroll, M A al-Janabi, K Solanki, J Bomanji |
Journal | Nephron
(Nephron)
Vol. 54
Issue 1
Pg. 47-52
( 1990)
ISSN: 1660-8151 [Print] Switzerland |
PMID | 2136939
(Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Angiotensin-Converting Enzyme Inhibitors
- Bridged Bicyclo Compounds
- Bridged-Ring Compounds
- Iodine Radioisotopes
- Oligopeptides
- Organotechnetium Compounds
- Technetium Tc 99m Mertiatide
- Ramipril
|
Topics |
- Adult
- Angiotensin-Converting Enzyme Inhibitors
(pharmacology)
- Bridged Bicyclo Compounds
(pharmacology)
- Bridged-Ring Compounds
(pharmacology)
- Cardiac Output
(drug effects)
- Humans
- Hypertension
(drug therapy, physiopathology)
- Iodine Radioisotopes
- Kidney Cortex
(blood supply, drug effects)
- Middle Aged
- Nephrons
(blood supply, drug effects)
- Oligopeptides
- Organotechnetium Compounds
- Ramipril
- Renal Circulation
(drug effects)
- Technetium Tc 99m Mertiatide
|